SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on November 10, 2023, the Compensation Committee of Crinetics’ Board of Directors…Read More
Crinetics Pharmaceuticals Inc Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635c4
